SuperNO₂VA™ Et, a mask that utilizes breakthrough technology to stent the airway open, helping avoid airway collapse while accurately monitoring end tidal carbon dioxide (EtCO2), has received an Innovative Technology designation from Vizient, Inc., the largest healthcare performance improvement company in the United States.

"Clinicians routinely tell us that SuperNO₂VA™ Et saves them precious time and allows them to care for high-risk patients with more confidence,” said Tammy Noll, Senior Vice President of Global Franchises. “Innovation is at the heart of what we do at Vyaire, and this recognition from the Vizient members reflects and acknowledges that commitment to reimagining what’s possible.” 

Each year, healthcare experts serving on Vizient member-led councils review and select products and technologies for their potential to enhance clinical care, patient safety, and healthcare worker safety or improve healthcare organizations' business operations. Innovative Technology designations are awarded to previously contracted products to signal to healthcare providers the impact of these innovations on patient care and the business models of healthcare organizations.

SuperNO₂VA™ Et uniquely maintains airway patency by delivering positive airway pressure and oxygenation to patients during deep sedation procedures. Clinical studies have shown SuperNO₂VA™ Et decreases hypoxemia and interventions, providing flexibility to deliver patient oxygenation before, during and after surgical procedures without the need for additional equipment.[i],[ii]   

“We chose to incorporate the SuperNO₂VA™ Et as an option for our anesthesia teams because it allows our team to provide a high level of care for our most at-risk patient populations,” said Dr. Delano Proctor, Director of Anesthesia at Cleveland Clinic Hillcrest Hospital. “It is now used routinely in the operating room and non-operating room anesthesia locations for patients with diagnosed and undiagnosed obstructive sleep apnea.”

“Healthcare experts on Vizient member councils evaluated SuperNO₂VA™ Et as part of the Innovative Technology Program,” Kelly Flaharty, Vizient senior director of contract services. “This designation indicates SuperNO₂VA™ Et has one or more qualities that differentiate it from similar products and has the potential to make an incremental improvement in healthcare. Congratulations to Vyaire.”

SuperNO₂VA™ Et launched in the United States in late 2021 and has since expanded into Europe and most recently Australia. Vyaire Medical exhibited SuperNO₂VA™ Et at the Vizient Innovative Technology Exchange in Dallas in October.

Vizient represents a diverse membership that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and represents approximately $130 billion in annual purchasing volume.

___________________________________________